Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA authorizes first device treatment for dry AMD ➤ Fast track designation granted to retinopathy of prematurity prevention therapy ➤ Fluorescent hydrogel for cataract surgery ➤ ASCRS news and events
➤ Positive topline Phase 3 data for presbyopia drop ➤ Topline results for oral therapy targeting geographic atrophy ➤ Positive topline results from Phase 2 sustained-delivery drug for DME ➤ Study assesses new virtual reality simulator for phaco ➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events
➤ FDA approves new ‘full range of vision’ IOL ➤ Imaging platform designed for patients in supine position receives FDA clearance ➤ Last patient dosed in Phase 3 study of non-IV, non-opioid sedation method ➤ Phase 2 study begins to assess neuropathic corneal pain treatment ➤ Plans to submit BLA for treatment of severe vision loss due to retinitis pigmentosa ➤ Research discovers protein related to AMD ➤ ASCRS news and events
➤ Last patient visit in proof-of-concept cell therapy ➤ Phase 2 data for allergic eye inflammation drop published ➤ NDA resubmission to the FDA for topical ocular reproxalap ➤ Positive topline results from Phase 2b suprachoroidal wet AMD therapy ➤ Complimentary access to video journal ➤ Partnership news ➤ ASCRS news and events
➤ Roll-out expanded for presbyopia-correcting IOL ➤ Study: Phase 3 clinical trials evaluate phentolamine ophthalmic solution ➤ AI listening innovation for ophthalmologists ➤ ASCRS news and events
➤ Research: quest for cataract reversal continues ➤ First allogenic cell therapy for treating corneal endothelial disease ➤ Enrollment complete in Phase 2b geographic atrophy treatment study ➤ European agency maintains negative opinion for intravitreal pegcetacoplan for geographic atrophy ➤ Companies partner to further development of new glaucoma drug ➤ ASCRS news and events
➤ FDA approves robotic OCT color fundus camera with OCTA ➤ Company to begin Phase 3 trial for Stargardt macular degeneration treatment ➤ 24-month results of oral treatment for geographic atrophy ➤ Positive Phase 2 results for investigational choroidal melanoma treatment ➤ Partnership news ➤ ASCRS news and events
➤ Whole-eye transplant 1 year later ➤ Phase 3 trial investigating new presbyopia drop therapy begins ➤ Study reports on multi-interventional glaucoma technique ➤ Topline results from Phase 3 trial for drug for active thyroid eye disease ➤ Pilot study complete for AMD treatment ➤ ASCRS news and events
➤ ASCRS mourns death of I. Howard Fine, MD ➤ New non-diffractive monofocal and toric IOLs ➤ 36-month results from clinical trials for new glaucoma device ➤ FDA grants IND to stem cell therapy intended to treat photoreceptor diseases ➤ Company launches ophthalmology-specific contract research organization ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.